ArticleJHEP reports : innovation in hepatology2021
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.
Article in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- CIRSE Standards of Practice on Transjugular Intrahepatic Portosystemic Shunts.Cardiovascular and interventional radiology · 2024Guideline
- A 7-mm Covered TIPS Reduces Hepatic Encephalopathy Without Increasing Rebleeding in Cirrhotic Patients With Small Liver: A Randomized Study.Liver international : official journal of the International Association for the Study of the Liver · 2026Trial
- Comments on Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Using Dedicated Versus Generic Stent-Grafts in Cirrhotic Patients.Cardiovascular and interventional radiology · 2026Article
- Fluoroscopic quantification of early in vivo expansion of VIATORR controlled expansion stent-grafts after TIPS: hemodynamic and clinical implications.Abdominal radiology (New York) · 2026Article
- Coaxial stent TIPS with 5 to 8 mm controlled expansion improving overall prognosis in cirrhotic patients: a prospective cohort study with target trial emulation.Hepatology international · 2026Article
- [Research advances on hepatic encephalopathy following transjugular intrahepatic portosystemic shunt].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Expandable Constrained Transjugular Intrahepatic Portosystemic Shunt: An Individualised Approach for High-Risk Patients?Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS.JHEP reports : innovation in hepatology · 2026Article
- Transjugular intrahepatic portosystemic shunt with ePTFE-covered stentgrafts: incidence and predictors of shunt dysfunction.Insights into imaging · 2025Article
- [Position paper for the standardized use of transjugular intrahepatic portosystemic shunt (TIPS) in adults].Zeitschrift fur Gastroenterologie · 2025Article
- Pre-emptive TIPS with 8-mm stents reduces hepatic encephalopathy without compromising efficacy in acute variceal bleeding.JHEP reports : innovation in hepatology · 2025Article
- Plasma Ammonia Levels Predict Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.United European gastroenterology journal · 2025Article
- Controlled expansion stent grafts versus legacy stent grafts for transjugular intrahepatic portosystemic shunt: a single-centre retrospective study on the incidence of hepatic encephalopathy.CVIR endovascular · 2025Article
- Nomogram for predicting survival after transjugular intrahepatic portosystemic shunt in portal hypertension patients with bleeding.World journal of gastrointestinal surgery · 2025Article
- Effect of portal pressure gradient reduction on outcomes after transjugular intrahepatic portosystemic shunt in portal hypertension patients.World journal of hepatology · 2025Article
- Evaluation of the Efficacy and Safety of Transjugular Intrahepatic Portosystemic Shunt Combined With Concurrent Antegrade Embolization of Large Spontaneous Portosystemic Shunts.Journal of medical imaging and radiation oncology · 2025Article
- The clinical relevance of acute-on-chronic liver failure in medical procedures: Endoscopy, interventions and surgery.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Which patients benefit the most? An update on transjugular intrahepatic portosystemic shunt.World journal of hepatology · 2025Review
- Acute-on-Chronic Liver Failure.Deutsches Arzteblatt international · 2025Review
- TIPS and hepatic encephalopathy in patients with cirrhosis.Metabolic brain disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsSmaller 8-mm diameter transjugular intrahepatic portosystemic shunts (TIPS) appear to be more beneficial than larger 10-mm TIPS stent-grafts, but lack the ability for secondary dilation in cases of clinical ineffectiveness. Underdilated VIATORR® TIPS stent grafts (VTS) expand passively, whereas novel VIATORR Controlled Expansion (VCX) stent grafts do not. This study evaluated the impact on survival of underdilated VCX compared with VTS in patients with decompensated cirrhosis.
methodsThis was a prospective case-control study including patients with cirrhosis receiving TIPS using 10-mm VCX underdilated to 8 mm. Patients with cirrhosis receiving 10-mm VTS underdilated to 8 mm were matched for age, sex, indication for TIPS, and liver function.
resultsA total of 114 patients (47 VCX, 47 VTS, and 20 fully dilated VCX/VTS) were included. After TIPS implantation, underdilated VCX diameter was 8.0 (7.8-9.2) mm at a median time of 359 (87-450) days, compared with VTS at 9.9 (9.7-10.0) mm (
conclusionsThis study demonstrated that VCX stent grafts underdilated to 8 mm do not passively expand to nominal diameter and suggests reduced hospital readmissions because of hepatic encephalopathy, uncontrolled ascites, and heart failure, and improved 1-year survival compared with underdilated VTS. LAY SUMMARY: Transjugular intrahepatic portosystemic shunt (TIPS) improves survival in selected patients with liver cirrhosis and acute variceal bleeding or refractory ascites. Smaller 8-mm diameter TIPS stent grafts appear to improve patient outcome compared with larger 10-mm diameter stent grafts. Novel VIATORR® Controlled Expansion (VCX) stent grafts facilitate safe and stable underdilation to 8 mm of large 10-mm diameter stent grafts with improved patient outcome (survival, hepatic encephalopathy, ascites and heart failure) compared with legacy VIATORR TIPS stent graft (VTS). Thus, the use of underdilated VCX could preserve heart function. CLINICAL TRIALS REGISTRATION: The study is registered at Clinicaltrials.govNCT03628807.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.